roflumilast 3 MG/ML Topical Foam [Zoryve]
roflumilast
RxCUI: 2671684
What the CMS Formulary Data Shows for roflumilast 3 MG/ML Topical Foam [Zoryve]
Per the CMS 2026 Part D formulary file, roflumilast 3 MG/ML Topical Foam [Zoryve] (RxNorm concept RXCUI 2671684, generic name roflumilast) appears on 7 distinct formulary files spanning 818 Medicare Part D plan offerings - 16.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 2 to Tier 4, with a cross-plan average of Tier 3.7.
Real-world access to roflumilast 3 MG/ML Topical Foam [Zoryve] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 14.3% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 59,491 Part D beneficiaries filled roflumilast 3 MG/ML Topical Foam [Zoryve] in 2023, with total plan-and-beneficiary spending of $60,127,502 and an average per-beneficiary annual cost of $1,010.70. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry roflumilast 3 MG/ML Topical Foam [Zoryve] today.
Coverage Details
- Formularies covering
- 7
- Plans covering
- 818
- Coverage rate
- 16.1%
- Tier range
- Tier 2 – Tier 4
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 100% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 14.3% of formularies
2023 Medicare Spending
- Beneficiaries
- 59,491
- Total spending
- $60,127,502
- Avg per beneficiary
- $1,010.70
Tier Distribution Across Plans
Standalone Drug Plans (PDP) Covering roflumilast 3 MG/ML Topical Foam [Zoryve]
5 standalone prescription drug plans include this drug.
| Plan | Insurer | Tier | PA | ST | Premium | States |
|---|---|---|---|---|---|---|
| AARP Medicare Rx Preferred from UHC (PDP) | UNITEDHEALTHCARE INS. CO. & UHC INS. CO. OF NY | T4 | Yes | No | $0 | - |
| AARP Medicare Rx Preferred from UHC (PDP) | UNITEDHEALTHCARE INS. CO. & UHC INS. CO. OF NY | T4 | Yes | No | $0 | - |
| AARP Medicare Rx Saver from UHC (PDP) | UNITEDHEALTHCARE INS. CO. & UHC INS. CO. OF NY | T4 | Yes | No | $0 | - |
| AARP Medicare Rx Saver from UHC (PDP) | UNITEDHEALTHCARE INS. CO. & UHC INS. CO. OF NY | T4 | Yes | No | $0 | - |
| AARP Medicare Rx Saver from UHC (PDP) | UNITEDHEALTHCARE INS. CO. & UHC INS. CO. OF NY | T4 | Yes | No | $0 | - |
Medicare Advantage Plans (MA-PD) Covering roflumilast 3 MG/ML Topical Foam [Zoryve]
95 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is roflumilast 3 MG/ML Topical Foam [Zoryve] covered by Medicare Part D?
Yes, roflumilast 3 MG/ML Topical Foam [Zoryve] is covered by 818 Medicare Part D plans (16.1% of all Part D formularies).
What tier is roflumilast 3 MG/ML Topical Foam [Zoryve] on Medicare Part D plans?
roflumilast 3 MG/ML Topical Foam [Zoryve] averages Tier 3.7 across Part D plans, ranging from Tier 2 to Tier 4.
Does roflumilast 3 MG/ML Topical Foam [Zoryve] require prior authorization?
100% of Part D formularies require prior authorization for roflumilast 3 MG/ML Topical Foam [Zoryve]. Step therapy: 0%. Quantity limits: 14.3%.
How much does Medicare spend on roflumilast 3 MG/ML Topical Foam [Zoryve]?
In 2023, total Medicare Part D spending on roflumilast 3 MG/ML Topical Foam [Zoryve] was $60,127,502, covering 59,491 beneficiaries. The average spend per beneficiary was $1,010.70.
Read our methodology - how this data is sourced, computed, and verified.